[go: up one dir, main page]

MX2018002344A - Metodo para tratar el cancer. - Google Patents

Metodo para tratar el cancer.

Info

Publication number
MX2018002344A
MX2018002344A MX2018002344A MX2018002344A MX2018002344A MX 2018002344 A MX2018002344 A MX 2018002344A MX 2018002344 A MX2018002344 A MX 2018002344A MX 2018002344 A MX2018002344 A MX 2018002344A MX 2018002344 A MX2018002344 A MX 2018002344A
Authority
MX
Mexico
Prior art keywords
treating cancer
inhibitor
ezh2
present disclosure
methods
Prior art date
Application number
MX2018002344A
Other languages
English (en)
Inventor
Keilhack Heike
K Knutson Sarah
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2018002344A publication Critical patent/MX2018002344A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a composiciones farmacóuticas que comprenden inhibidor(es) de la histona metiltransferasa EZH2 humana, y a métodos de terapia contra el cáncer que usan el/los inhibidor(es) de EZH2.
MX2018002344A 2015-08-24 2016-08-24 Metodo para tratar el cancer. MX2018002344A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562209304P 2015-08-24 2015-08-24
PCT/US2016/048401 WO2017035234A1 (en) 2015-08-24 2016-08-24 Method for treating cancer

Publications (1)

Publication Number Publication Date
MX2018002344A true MX2018002344A (es) 2018-07-06

Family

ID=58100964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002344A MX2018002344A (es) 2015-08-24 2016-08-24 Metodo para tratar el cancer.

Country Status (12)

Country Link
US (4) US10493076B2 (es)
EP (1) EP3341080A4 (es)
JP (1) JP2018525414A (es)
KR (1) KR20180042356A (es)
CN (1) CN108025191A (es)
AU (2) AU2016312514A1 (es)
CA (1) CA2996412A1 (es)
EA (1) EA201890567A1 (es)
IL (2) IL307260A (es)
MX (1) MX2018002344A (es)
SG (1) SG10201909199PA (es)
WO (1) WO2017035234A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024907A2 (pt) 2011-03-28 2016-12-20 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
IL308613A (en) 2012-10-15 2024-01-01 Epizyme Inc Cancer treatment methods
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
CN108349958B (zh) * 2015-09-25 2022-02-15 Epizyme股份有限公司 用ezh2抑制剂治疗mrto/sccoht的方法
JP2018532761A (ja) * 2015-11-06 2018-11-08 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
MA53236A (fr) * 2018-08-14 2021-06-23 Mei Pharma Inc Traitement des malignités des lymphocytes b

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7056883B2 (en) 2003-06-27 2006-06-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20110064664A1 (en) 2007-10-08 2011-03-17 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
JP5889875B2 (ja) 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
CN102970869B (zh) 2010-05-07 2014-07-16 葛兰素史密斯克莱有限责任公司 吲哚
WO2012071096A2 (en) 2010-09-03 2012-05-31 The Johns Hopkins University Arid1a and ppp2r1a mutations in cancer
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
ES2655642T3 (es) 2011-05-16 2018-02-21 Ulrike Nuber Terapias contra el cáncer novedosas y métodos
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
CN103987842A (zh) 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
WO2013059944A1 (en) 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP6321619B2 (ja) 2012-03-12 2018-05-09 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤およびその使用方法
EP2828250B1 (en) 2012-03-19 2021-03-10 Imperial College Innovations Limited Quinazoline compounds and their use in therapy
PL2836491T3 (pl) 2012-04-13 2017-08-31 Epizyme, Inc. Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2
IL308807B2 (en) 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
IL308613A (en) 2012-10-15 2024-01-01 Epizyme Inc Cancer treatment methods
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014092905A1 (en) 2012-12-10 2014-06-19 Children's Medical Center Corporation Methods and assays for combination treatment of cancer
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
ME02730B (me) 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014176047A1 (en) 2013-04-25 2014-10-30 Novartis Ag Markers for ezh2 inhibitors
EA030196B1 (ru) 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
AU2014276417B2 (en) 2013-06-06 2016-11-24 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
US20160326596A1 (en) 2013-12-31 2016-11-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function
EP3111222A1 (en) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EP3114125A1 (en) 2014-03-07 2017-01-11 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
LT3157527T (lt) 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
SG10202007972SA (en) 2014-06-19 2020-10-29 Memorial Sloan Kettering Cancer Center Biomarkers for response to ezh2 inhibitors
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN111494378A (zh) 2014-09-05 2020-08-07 艾科尔公司 用于治疗增生性病症的组合物和方法
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
MX383484B (es) 2014-11-17 2025-03-11 Epizyme Inc Método para tratar el cáncer.
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
MX387885B (es) 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
CN108349958B (zh) 2015-09-25 2022-02-15 Epizyme股份有限公司 用ezh2抑制剂治疗mrto/sccoht的方法
WO2017062495A2 (en) 2015-10-06 2017-04-13 Epizyme, Inc. Method of treating medulloblastoma with an ezh2 inhibitor
JP2018532761A (ja) 2015-11-06 2018-11-08 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与
IL302914A (en) 2015-12-07 2023-07-01 Epizyme Inc Inhibitors of ezh2 and methods of use thereof
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
US20190038633A1 (en) 2016-02-08 2019-02-07 Epizyme, Inc. Methods of treating cancer
US20200129519A1 (en) 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20190350929A1 (en) 2017-02-02 2019-11-21 Epizyme, Inc. Cancer treatment modalities

Also Published As

Publication number Publication date
AU2022202118A1 (en) 2022-04-14
AU2016312514A1 (en) 2018-03-15
CN108025191A (zh) 2018-05-11
SG10201909199PA (en) 2019-11-28
EP3341080A1 (en) 2018-07-04
EA201890567A1 (ru) 2018-08-31
US20180235975A1 (en) 2018-08-23
US20200155561A1 (en) 2020-05-21
US20240024331A1 (en) 2024-01-25
CA2996412A1 (en) 2017-03-02
IL307260A (en) 2023-11-01
US11642349B2 (en) 2023-05-09
EP3341080A4 (en) 2019-03-20
US10898490B2 (en) 2021-01-26
JP2018525414A (ja) 2018-09-06
IL257691A (en) 2018-04-30
US20210213027A1 (en) 2021-07-15
KR20180042356A (ko) 2018-04-25
US10493076B2 (en) 2019-12-03
WO2017035234A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
MX2018002344A (es) Metodo para tratar el cancer.
MX383484B (es) Método para tratar el cáncer.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
MX2016007351A (es) Terapia de combinacion para tratar cancer.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX391720B (es) Terapia combinada para tratar cáncer.
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2019001125A (es) Inhibidores de cinasa macrociclica.
WO2016025635A3 (en) Combination therapy for treating cancer
NZ700759A (en) Combination therapy for treating cancer
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PH12018500423A1 (en) Inhibitors of ezh2
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
WO2016043874A3 (en) Combination therapy for treating cancer
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX394452B (es) Inhibicion de la actividad de olig2.
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
ZA201901367B (en) Inhibition of olig2 activity
MX2017003463A (es) Inhibidores de histona desmetilasa.
WO2015156674A3 (en) Method for treating cancer